|Last Price||Today's Change||52-Week Range||Trading Volume|
|65.78||0.53 (+0.81%)||45.50 - 70.76||3.4 million (Below Avg)|
Market data as of 2:41PM 12/17/14. Quotes are delayed by at least 15 min.
AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting
12/07/2014 8:15 PM ET